Symposium: Lutonix® DCB – Discussion on pre-clinical saftey studies, new insights from LEVANT2, Real World experience and the role of DCB in treatment of critical limb ischemia
Date:
Jan 28, 2015
Room:
Main Arena 1
Start:
13:30
End:
15:00
Role:
Moderator
Title:
Role of DCBs in treating critical limb ischemia and the enrollment update
on-going Lutonix® BTK clinical trial
Date:
Jan 28, 2015
Room:
Main Arena 1
Start:
14:40
End:
14:47
Role:
Speaker
Title:
The great debate: Are all DCB equal?
Date:
Jan 29, 2015
Room:
Discussion Forum
Start:
12:30
End:
13:30
Role:
Discussant
Title:
DCB are still a valid option to solve the challenge of BTK vessel patency: Lutonix BTK trials are continuing
Date:
Jan 29, 2015
Room:
Discussion Forum
Start:
13:05
End:
13:12
Role:
Speaker
Title:
Complications in the cathlab, and what the team learned from it
Accidental placement of an internal jugular 8 french sheath in vertebral artery with bleeding and thrombus hanging off of sheath in vertebral artery – endovascular treatment
Date:
Jan 28, 2015
Room:
Global Expert Exchange
Start:
10:25
End:
10:30
Role:
Speaker
Title:
Thrombolytic therapy of DVT & PE in pregnancy – review of risks, benefits and therapy including radiation risks
Optimizing the accuracy of the Trivascular ovation aortic aneurysm stent graft in short neck situtations: A novel pre-deployment use of contrast enhanced visualization of the main body seal zone
Date:
Jan 28, 2015
Room:
Global Expert Exchange
Start:
12:42
End:
12:48
Role:
Speaker
Title:
Optical coherence tomography in the intraoperative evaluation of the SUPERA self expanding stenting system
Filter protected carotid angioplasty: Prospective analysis of microscopic findings of embolic material and correlation with clinical and morphological characteristics in 400 cases
Date:
Jan 27, 2015
Room:
Technical Forum
Start:
10:37
End:
10:44
Role:
Speaker
Title:
Concepts and techniques in oncologic and non-oncologic embolizations
Evolving strategies and economic considerations in treatment of femoropopliteal arterial disease
Date:
Jan 27, 2015
Room:
Main Arena 1
Start:
8:20
End:
8:30
Role:
Speaker
Title:
Asymptomatic carotid stenosis: What will CREST 2 tell us what we don’t already know?
Date:
Jan 27, 2015
Room:
Technical Forum
Start:
9:14
End:
9:21
Role:
Speaker
Title:
Changing paradigms and future concepts in peripheral interventions
Date:
Jan 27, 2015
Room:
Main Arena 1
Start:
9:30
End:
11:00
Role:
Moderator
Title:
My take-home messages from LEVANT II and In.Pact SFA – a critical review
Date:
Jan 27, 2015
Room:
Main Arena 1
Start:
9:40
End:
9:45
Role:
Speaker
Title:
Critical limb ischemia treatment 2014: Lessons learned, current status and future perspectives
Date:
Jan 28, 2015
Room:
Main Arena 1
Start:
9:30
End:
11:00
Role:
Moderator
Title:
The BEST-CLI Trial: Open vs. endovascular therapy for critical limb ischemia
Date:
Jan 28, 2015
Room:
Main Arena 1
Start:
9:40
End:
9:45
Role:
Speaker
Title:
Symposium: Lutonix® DCB – Discussion on pre-clinical saftey studies, new insights from LEVANT2, Real World experience and the role of DCB in treatment of critical limb ischemia
Date:
Jan 28, 2015
Room:
Main Arena 1
Start:
13:30
End:
15:00
Role:
Chairman
Title:
VIVA @ LINC: Renal and visceral disease: pressing new dilemmas and pushing the field forward
Date:
Jan 28, 2015
Room:
Main Arena 1
Start:
15:00
End:
16:30
Role:
Moderator
Title:
CORAL trial aftermath: What do we do now? Renal revascularisation in perspective
Date:
Jan 28, 2015
Room:
Main Arena 1
Start:
15:05
End:
15:13
Role:
Speaker
Title:
Controversial issues and open questions in venous interventions
Date:
Jan 29, 2015
Room:
Discussion Forum
Start:
9:30
End:
10:30
Role:
Discussant
Title:
How to select appropriate endpoints and measure success?
Date:
Jan 29, 2015
Room:
Discussion Forum
Start:
9:46
End:
9:54
Role:
Speaker
Title:
The great debate: Are all DCB equal?
Date:
Jan 29, 2015
Room:
Discussion Forum
Start:
12:30
End:
13:30
Role:
Chairman
Title:
VIVA @ LINC: The worst complication I had this year. What did I learn?
Date:
Jan 29, 2015
Room:
Discussion Forum
Start:
15:00
End:
16:30
Role:
Chairman
Jenkins, Michael
Consultant Vascular Surgeon
London,
United Kingdom
Alternative approach to end stage critical limb ischemia
Date:
Jan 27, 2015
Room:
Global Expert Exchange
Start:
16:00
End:
16:45
Role:
Chairman
Title:
The challenge of vessel calcification in different vascular beds: What are we dealing with?
Date:
Jan 27, 2015
Room:
Main Arena 1
Start:
17:25
End:
17:32
Role:
Speaker
Title:
Meet the CTO Experts
Date:
Jan 27, 2015
Room:
Westin Hotel
Start:
19:00
End:
21:00
Role:
Moderator
Title:
Pioneering techniques in tibial interventions
Date:
Jan 27, 2015
Room:
Westin Hotel
Start:
19:00
End:
19:10
Role:
Speaker
Title:
How I would have treated this case
Date:
Jan 27, 2015
Room:
Westin Hotel
Start:
19:25
End:
19:30
Role:
Speaker
Title:
How I would have treated this case
Date:
Jan 27, 2015
Room:
Westin Hotel
Start:
20:15
End:
20:20
Role:
Speaker
Title:
Symposium: Lutonix® DCB – Discussion on pre-clinical saftey studies, new insights from LEVANT2, Real World experience and the role of DCB in treatment of critical limb ischemia
Date:
Jan 28, 2015
Room:
Main Arena 1
Start:
13:30
End:
15:00
Role:
Moderator
Title:
Discussion on physiology of CLI in utility of DCB in below-the-knee procedures
Date:
Jan 28, 2015
Room:
Main Arena 1
Start:
14:47
End:
14:54
Role:
Speaker
Title:
Scrub in with the experts: The last frontiers: Below-the-ankle disease
Date:
Jan 28, 2015
Room:
Technical Forum
Start:
16:30
End:
18:00
Role:
Moderator
Title:
The last frontiers: Endovascular treatment of common femoral artery lesions and pioneering solutions for TASC D+ lesions
Lunch symposium: Expanding peripheral treatment options with Penumbra technology in embolization and thrombectomy
Date:
Jan 27, 2015
Room:
Technical Forum
Start:
12:35
End:
13:20
Role:
Moderator
Title:
Indigo™ System – provide rapid restoration of flow to thrombosed vessels in the peripheral vasculature introducing the largest extraction lumen designed for BTK vessels.
Endovascular repair of ruptured abdominal aortic aneurysms is superior to open repair in risk stratified patients: a look at the United States experience through the SVS vascular quality initiative 2003–2013